What makes this “wakefulness” drug unusual is that it is not related to amphetamine (like Adderal is). It can be useful off-label to combat the crushing fatigue that comes with chronic pain.
Breckenridge Pharmaceutical, Inc. has announced that its Abbreviated New Drug Application (ANDA) for armodafinil tablets has received final approval from the FDA.
The tablets, which are being created in 50-mg, 150-mg and 250-mg doses, are generic versions of Nuvigil from Cephalon, the subsidiary of Teva Pharmaceutical Industries.
Armodafinil is designed to improve wakefulness in adult patients with excessive sleepiness due to obstructive sleep apnea, narcolepsy, or shift work disorder.